Menopause HRT — hormone replacement therapy — is the single most effective treatment for menopause symptoms, and probably the most misunderstood. The 2002 WMI trial headlines scared a generation away from it; the 2023-2024 reanalyses rehabilitated it for most women under 60. If you are weighing it, you deserve clear numbers, not vibes.
This guide covers who HRT helps most, the real 2024 risk picture, body-identical versus synthetic, how to pick a route, and the decision framework your doctor may not have time to walk you through.
What menopause HRT actually is
HRT replaces the hormones your ovaries stop making. For most women, that means estrogen, paired with progesterone if you still have a uterus. Some protocols add low-dose testosterone for libido and energy. HRT is not a "menopause cure" — it is symptom relief and long-term risk modification, dosed to your body and circumstances.
Two hormones, six delivery routes, and decades of evolving evidence. The right protocol for you depends on your symptoms, health history, and life stage.
Who benefits most from HRT
The 2022-2024 consensus from NICE, The Menopause Society, and the IMS: HRT benefits outweigh risks for most women under 60 or within 10 years of their final period — the so-called "window of opportunity." Strongest-benefit groups:
- Women with moderate to severe hot flashes or night sweats
- Women with genitourinary symptoms (vaginal dryness, urinary urgency, painful sex) — localized estrogen has essentially no systemic risk
- Women with premature menopause (before 40) or early menopause (40-45) — HRT here replaces what should still be present and is protective until at least the normal menopause age
- Women with fragile bones or high fracture risk
- Women with severe perimenopausal anxiety or mood symptoms with a cyclical pattern
Women less likely to benefit: mild symptoms that respond to lifestyle, those far past menopause (10+ years) starting HRT for the first time, or those with contraindications (see below).
The real risk picture in 2024
Headlines from the original WHI trial overstated risks because the cohort was older (average 63), used oral conjugated equine estrogens (different from modern body-identical preparations), and studied synthetic progestin. Reanalysis by age and route tells a very different story.
Breast cancer
Combined HRT (estrogen + synthetic progestin) taken for 5+ years is associated with about 8 extra cases per 10,000 women per year — lower than the extra risk from obesity, 2+ drinks per day, or physical inactivity. Estrogen-only HRT (for women without a uterus) shows no increase and may slightly reduce risk. Micronised progesterone (body-identical) appears safer than older synthetic progestins.
Blood clots and stroke
Transdermal estrogen (patches, gels, sprays) carries no measurable increase in venous thromboembolism or stroke risk — a major shift from the oral-only risk profile of older trials. If you are over 60, obese, or have a clotting history, transdermal is the safer route.
Cardiovascular disease
Started within the window of opportunity, HRT is broadly cardioprotective — reducing coronary disease incidence by roughly 30 percent. Started in your seventies, the signal reverses. This is the single biggest reason for the "window" framing.
Endometrial cancer
Estrogen without progesterone in a woman with a uterus is a clear risk. Combined regimens (estrogen + any form of progesterone) neutralise it. This is why you cannot have estrogen-only HRT if you still have a uterus.
Body-identical vs synthetic: what the terms actually mean
Body-identical (often called "bioidentical" in the US) means the molecule is structurally the same as what your ovaries produce. Body-identical 17β-estradiol and micronised progesterone are regulated pharmaceuticals — the same stuff, prescribed by the same doctors, covered by the same insurers.
The marketing term "bioidentical hormone replacement therapy" (BHRT), as sold by compounding pharmacies and wellness clinics, often refers to unregulated custom mixes with unclear dosing. These are not the same thing. Medical societies oppose unregulated compounded BHRT.
Regulated body-identical HRT is the current standard of care when available. It is what you want.
Picking a route: patches, gels, pills, rings
- Transdermal estrogen (patch, gel, spray) — preferred default. No first-pass liver effect, lowest clot risk, flexible dosing.
- Oral estrogen — cheaper, simpler, but higher clot risk. Fine for lower-risk women under 60.
- Micronised progesterone (oral capsule at night) — current standard for endometrial protection and often helps menopause insomnia.
- Localized vaginal estrogen (cream, ring, tablet) — for genitourinary symptoms only. Minimal systemic absorption. Safe for most women, including many breast cancer survivors.
- Combined patches — estrogen + progestogen in one patch. Convenient, less flexible for dose adjustment.
- Low-dose testosterone — usually transdermal cream, off-label in most countries, prescribed for persistent low libido after estrogen optimization.
Who should not take HRT
Absolute contraindications:
- Current or recent estrogen-sensitive breast cancer (some localized vaginal forms are still possible — talk to your oncologist)
- Unexplained vaginal bleeding
- Active clotting disorder or recent VTE
- Active liver disease
- Untreated severe hypertension
- Pregnancy
Relative contraindications (transdermal is usually still possible): previous VTE, severe migraine with aura, active lupus, gallbladder disease, high BMI.
How to have the conversation
Your first HRT appointment does not have to feel like an interrogation. Bring:
- A symptom log (2-4 weeks minimum) — frequency of hot flashes, sleep disruption, mood patterns, cycle irregularity
- Your personal risk factors: family history of breast cancer and VTE, current medications, BMI, blood pressure, smoking status
- Your priorities: symptom relief, bone protection, libido, cognition
- The three questions that matter: "Am I a candidate? Which formulation do you recommend for my profile? What is our review schedule?"
NHS HRT guidance and The Menopause Society publish decision aids that can make the conversation shorter.
Frequently asked questions
How long can I safely stay on HRT?
There is no fixed cutoff. Current guidance supports individualised HRT at the lowest effective dose, reviewed annually. Many women stay on it into their sixties or seventies when benefits continue to outweigh risks.
Does HRT cause weight gain?
No, on average. Weight gain in midlife is driven by declining muscle mass, cortisol shifts, and sleep loss — not by HRT itself. Transdermal estrogen may actually reduce central fat accumulation modestly.
Will HRT restore my libido?
Sometimes fully, sometimes partly. Estrogen relieves vaginal dryness and sleep issues that kill libido indirectly. Direct libido effects often need low-dose testosterone in addition. Patience: 3-6 months to judge.
What if I have to stop HRT?
Taper rather than stop abruptly — this reduces rebound hot flashes. Most women do not need HRT forever, but there is no penalty for staying on it longer if it still helps.
One decision at a time
HRT is not a life sentence and not a magic wand. Book a 30-minute appointment with a GP or menopause specialist (not a compounding pharmacy), start on a standard regimen, review at 3 months. Most women know within that window whether HRT is right for them.
Track your symptoms, energy, sleep, and mood with Passage before and after starting HRT — the before/after data is the best argument for adjusting dose or staying the course.
